Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Companies Deals

Genentech Joins Hunt For ‘Molecular Glue’ Drugs With Orionis

Will Aim At ‘Undruggable’ Oncology and Neurodegeneration Targets

  • News

Executive Summary

Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.

You may also be interested in...



Deal Watch: Merck KGAA Teams With AI Biotechs On Drug Discovery Efforts

Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.

RayzeBio And Genentech Show Interest In Radiopharmaceuticals Continues To Grow

RayzeBio's IPO and Genentech's first buy-in into the field show a wave of next-generation companies hoping to expand the radiopharmaceutical field.

Roche Looks To Muscle Into Obesity Market With $2.7bn Carmot Buyout

The Swiss pharma sees the acquisition as the ‘backbone’ for its future cardiometabolic portfolio, which could include a combination with a muscle-building therapy.

Table

View full table

Topics

Related Companies

Tags:
Commercial Companies Deals
Latest Headlines

China Seniors' Rising HIV Rates Pose Control Challenges

Seismic Rumbles Into Clinic With $121m For Novel Immunology Biologics

EyePoint Hits New Durability Milestone For Wet AMD Treatment

Roche Looks To Muscle Into Obesity Market With $2.7bn Carmot Buyout

See All
UsernamePublicRestriction

Register

SC149085

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By